Table 2.
Characteristics of the population according to the presence or not of post-COVID-19 syndrome.
| Continuous variables, mean (SD) | Without post-COVID-19 syndrome N = 88 |
With post-COVID-19 syndrome N = 112 |
p |
|---|---|---|---|
| Age, years | 50.0 (15.4) | 47.9 (13.4) | 0.296 |
| Body mass index, kg/m2 | 26.6 (5.8) | 26.3 (6.8) | 0.694 |
| Total cholesterol, mg/dl | 182.9 (43.2) | 184.9 (34.7) | 0.744 |
| LDL-C, mg/dl | 107.2 (39.6) | 108.9 (31.0) | 0.780 |
| HDL-C, mg/dl | 51.2 (14.5) | 52.1 (15.2) | 0.709 |
| Triglycerides, mg/dl | 137.5 (160.2) | 128.4 (66.1) | 0.664 |
| Blood glucose, mg/dL | 99.0 (14.9) | 100.9 (18.8) | 0.476 |
| Time between the COVID-19 diagnosis and the CPET, days | 81.9 (21.8) | 78.8 (20.5) | 0.448 |
| Categorical variables, % | |||
| Male gender | 63.6 | 41.1 | 0.002 |
| Cardiovascular history | 15.9 | 2.7 | 0.001 |
| Hypertension | 30.7 | 26.1 | 0.478 |
| Dyslipidemia | 29.1 | 20.2 | 0.150 |
| Type 2 diabetes | 4.6 | 6.3 | 0.613 |
| Current smoking | 3.4 | 8.0 | 0.171 |
| Chronic obstructive pulmonary disease | 0.0 | 2.6 | 0.176 |
| Treatment | |||
| ACE inhibitors angiotensin antagonists | 23.9 | 22.5 | 0.824 |
| Beta-adrenergic blockers | 22.7 | 9.8 | 0.01 |
| Statins | 27.3 | 16.1 | 0.054 |
| Aspirin | 17.1 | 4.5 | 0.003 |
| Calcium channel blockers | 11.4 | 7.1 | 0.301 |
| Required hospitalization | 19.3 | 19.6 | 0.954 |
| Required oxygen therapy | 64.7 | 68.2 | 0.819 |
| Required admission to intensive care | 17.7 | 13.6 | 0.731 |